Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 5 Similar Profiles
Therapeutics Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Safety Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1999 2017

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Garzon, R., Savona, M., Baz, R., Andreeff, M., Gabrail, N., Gutierrez, M., Savoie, L., Mau-Sorensen, P. M., Wagner-Johnston, N., Yee, K., Unger, T. J., Saint-Martin, J. R., Carlson, R., Rashal, T., Kashyap, T., Klebanov, B., Shacham, S., Kauffman, M. & Stone, R. Jun 15 2017 In : Blood. 129, 24, p. 3165-3174 10 p.

Research output: Research - peer-reviewArticle

Clinical Trials, Phase I
Acute Myeloid Leukemia
KPT-330
Toxicity
Refractory materials

A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma

Czuczman, M. S. , Trněný, M. , Davies, A. , Rule, S. , Linton, K. M. , Wagner-Johnston, N. , Gascoyne, R. D. , Slack, G. W. , Brousset, P. , Eberhard, D. A. , Hernandez-Ilizaliturri, F. J. , Salles, G. , Witzig, T. E. , Zinzani, P. L. , Wright, G. W. , Staudt, L. M. , Yang, Y. , Williams, P. M. , Lih, C. J. , Russo, J. & 5 others Thakurta, A., Hagner, P., Fustier, P., Song, D. & Lewis, I. D. Aug 1 2017 In : Clinical Cancer Research. 23, 15, p. 4127-4137 11 p.

Research output: Research - peer-reviewArticle

Lymphoma, Large B-Cell, Diffuse
B-Lymphocytes
Research Personnel
Safety
lenalidomide

A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma

Maly, J. J., Christian, B. A., Zhu, X., Wei, L., Sexton, J. L., Jaglowski, S. M., Devine, S. M., Fehniger, T. A., Wagner-Johnston, N. D., Phelps, M. A., Bartlett, N. L. & Blum, K. A. Jun 1 2017 In : Clinical Lymphoma, Myeloma and Leukemia. 17, 6, p. 347-353 7 p.

Research output: Research - peer-reviewArticle

Hodgkin Disease
panobinostat
lenalidomide
Lymphocytes
Safety

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

Jones, J. A., Robak, T., Brown, J. R., Awan, F. T., Badoux, X., Coutre, S., Loscertales, J., Taylor, K., Vandenberghe, E., Wach, M., Wagner-Johnston, N., Ysebaert, L., Dreiling, L., Dubowy, R., Xing, G., Flinn, I. W. & Owen, C. Mar 1 2017 In : The Lancet Haematology. 4, 3, p. e114-e126

Research output: Research - peer-reviewArticle

B-Cell Chronic Lymphocytic Leukemia
Safety
ofatumumab
idelalisib
Therapeutics

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study

Salles, G., Schuster, S. J., De Vos, S., Wagner-Johnston, N. D., Viardot, A., Blum, K. A., Flowers, C. R., Jurczak, W. J., Flinn, I. W., Kahl, B. S., Martin, P., Kim, Y., Shreay, S., Will, M., Sorensen, B., Breuleux, M., Zinzani, P. L. & Gopal, A. K. Mar 31 2017 In : Haematologica. 102, 4, p. e156-e159

Research output: Research - peer-reviewLetter

Follicular Lymphoma
Alkylating Agents
Safety
Rituximab
idelalisib